New President and CEO of AddLifeNew CEO of AddLife
We are excited to announce, that as of today, we have a new CEO, Fredrik Dalborg. Fredrik is succeeding Kristina Willgård, our former CEO of seven successful years since AddLife started.
We welcome Fredrik and look forward to working with him!
AddLife creates value
The laboratory and medical technology market is relatively insensitive to economic fluctuations. Growth tends to be stable and is mainly driven by population growth and an ageing population. These trends increase the demand for AddLife's healthcare and research products. Historically, the markets where we operate have grown at an annual rate of 2-4 percent.
AddLife’s subsidiaries are strongly cash generative, which gives financial opportunity for acquisitions and investments.
AddLife has substantial experience of acquisitions, identifying candidates and completing successful transactions.
AddLife’s subsidiaries have strong sales organisations with high technological expertise and long term customer relationships.
Target fulfilment 2021
The investor pages contain all published financial information to facilitate investment decisions.
We are happy to assist you in understanding our business and financial results. Please do not hesitate to contact us if you would like more information, or if you have any suggestions for improving our service.
IR- and press contacts
Your subscription is now saved and you will receive an email to verify your email address and activate the subscription.